Advances in Treatment Strategies for COVID-19: Insights from Other Coronavirus Diseases and Prospects

Overview

Journal Biosaf Health

Date 2025 Mar 13

PMID 40078910

Authors

Yingwen Li

Jiaming Lan

Gary Wong

Affiliations

Soon will be listed here.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is the third human disease outbreak caused by an emerging coronavirus in the 21st century. Caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the COVID-19 pandemic has been the most devastating, with millions of deaths. Medical countermeasures are needed to limit the number of infections and fatalities. Here, we discuss advances in clinical and research-based treatment methods for SARS-CoV-2 that were initially derived from treatments for other coronaviruses. Recent advances in SARS-CoV-2 treatments, from traditional drugs and immunotherapies to artificial intelligence to predict potential future treatment methods, are summarized and discussed.

References

Sun L, Xu K, Huang W, Yang Y, Li P, Tang L . Predicting dynamic cellular protein-RNA interactions by deep learning using in vivo RNA structures. Cell Res. 2021; 31(5):495-516. PMC: 7900654. DOI: 10.1038/s41422-021-00476-y. View

Broughton J, Deng X, Yu G, Fasching C, Servellita V, Singh J . CRISPR-Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020; 38(7):870-874. PMC: 9107629. DOI: 10.1038/s41587-020-0513-4. View

Strohbehn G, Heiss B, Rouhani S, Trujillo J, Yu J, Kacew A . COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2020; 109(3):688-696. PMC: 7753375. DOI: 10.1002/cpt.2117. View

Tian W, Zhang N, Jin R, Feng Y, Wang S, Gao S . Immune suppression in the early stage of COVID-19 disease. Nat Commun. 2020; 11(1):5859. PMC: 7673112. DOI: 10.1038/s41467-020-19706-9. View

Walz L, Cohen A, Rebaza A, Vanchieri J, Slade M, Dela Cruz C . JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. BMC Infect Dis. 2021; 21(1):47. PMC: 7797881. DOI: 10.1186/s12879-020-05730-z. View

Stebbing J, Krishnan V, de Bono S, Ottaviani S, Casalini G, Richardson P . Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med. 2020; 12(8):e12697. PMC: 7300657. DOI: 10.15252/emmm.202012697. View

Xia S, Lan Q, Su S, Wang X, Xu W, Liu Z . The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transduct Target Ther. 2020; 5(1):92. PMC: 7289711. DOI: 10.1038/s41392-020-0184-0. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Bannerman B, Julvez J, Oarga A, Blundell T, Moreno P, Floto R . Integrated human/SARS-CoV-2 metabolic models present novel treatment strategies against COVID-19. Life Sci Alliance. 2021; 4(10). PMC: 8343166. DOI: 10.26508/lsa.202000954. View

10.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

11.

Sun L, Li P, Ju X, Rao J, Huang W, Ren L . In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs. Cell. 2021; 184(7):1865-1883.e20. PMC: 7871767. DOI: 10.1016/j.cell.2021.02.008. View

12.

Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti J . Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014; 514(7520):47-53. PMC: 4214273. DOI: 10.1038/nature13777. View

13.

Berber B, Aydin C, Kocabas F, Guney-Esken G, Yilancioglu K, KaradaG-Alpaslan M . Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics. Gene Ther. 2020; 28(6):290-305. PMC: 7734466. DOI: 10.1038/s41434-020-00209-7. View

14.

. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022; 399(10325):665-676. PMC: 8830904. DOI: 10.1016/S0140-6736(22)00163-5. View

15.

Cantuti-Castelvetri L, Ojha R, Pedro L, Djannatian M, Franz J, Kuivanen S . Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020; 370(6518):856-860. PMC: 7857391. DOI: 10.1126/science.abd2985. View

16.

Yoon J, Toots M, Lee S, Lee M, Ludeke B, Luczo J . Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses. Antimicrob Agents Chemother. 2018; 62(8). PMC: 6105843. DOI: 10.1128/AAC.00766-18. View

17.

Nguyen H, Wilson H, Jayakumar S, Kulkarni V, Kulkarni S . Efficient Inhibition of HIV Using CRISPR/Cas13d Nuclease System. Viruses. 2021; 13(9). PMC: 8473377. DOI: 10.3390/v13091850. View

18.

Kocivnik N, Velnar T . A Review Pertaining to SARS-CoV-2 and Autoimmune Diseases: What Is the Connection?. Life (Basel). 2022; 12(11). PMC: 9698792. DOI: 10.3390/life12111918. View

19.

Wang S, Qiu Z, Hou Y, Deng X, Xu W, Zheng T . AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. Cell Res. 2021; 31(2):126-140. PMC: 7791157. DOI: 10.1038/s41422-020-00460-y. View

20.

Agostini M, Pruijssers A, Chappell J, Gribble J, Lu X, Andres E . Small-Molecule Antiviral β-d--Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. J Virol. 2019; 93(24). PMC: 6880162. DOI: 10.1128/JVI.01348-19. View